Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
125actual
Sites
18
Countries
Canada, Israel, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-11 | actual | When the study began enrolling |
| Primary completion | 2025-07-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-02 | actual | The whole study's end, after follow-up |
| First posted | 2021-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Neoplasm
Interventions
- Drug: SAR444881 — also filed as BND-22
- Drug: Pembrolizumab
- Drug: Cetuximab
- Drug: Carboplatin
- Drug: Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFPart 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)
measured Cycle 1 (28 days)
Part 1: Incidence of treatment-emergent adverse events and serious adverse events
measured Through study completion, an average of 5 months
Part 2: Objective Response Rate (ORR) per RECIST v1.1
measured Through study completion, an average of 3 months
Publications
- PMID 36096532 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed